Increasing rates of <i>erm</i> (B) and <i>erm</i> (N) in human <i>Campylobacter coli</i> and <i>Campylobacter jejuni</i> erythromycin-resistant isolates between 2018 and 2023 in France

Macrolides are the first-line compounds used for the treatment of campylobacteriosis. Macrolide resistance remains low in France, with mutations in <i>23S rDNA</i> being the main associated resistance mechanism. However, two erythromycin methyltransferases have also been identified<i>: erm</i>(B), which is mainly described in animal reservoirs, and <i>erm</i>(N), which is strictly described in humans. In France, between 2018 and 2023, erythromycin-resistant <i>Campylobacter</i> species strains were systematically sequenced and analyzed <i>via</i> an in-house bioinformatics pipeline, leading to the identification of the resistomes, MLST and cgMLST, as well as the characterization of the source of contamination. In this study, the genomes of 280 erythromycin-resistant strains were sequenced over a 6-year period. The identification of erythromycin-associated resistance markers revealed a predominance of <i>23S rDNA</i> mutations, in 90% of cases, but also <i>erm</i>-type methyltransferases in 10% of cases: 75% for <i>erm</i>(N) and 25% for <i>erm</i>(B). Over this period, an important increase in the rate of <i>erm</i>-positive isolates was observed: 2% in 2018 compared with 13% in 2023, with 10% for <i>erm</i>(N) and 3% for <i>erm</i>(B). <i>erm</i>(N) has been found exclusively within a CRISPR-Cas9 operon, whereas <i>erm</i>(B) has been found within diverse types of resistance genomic islands. Each <i>erm</i>(N)- or <i>erm</i>(B)-positive isolate had at least two other resistance markers (mostly ciprofloxacin, tetracycline, or ampicillin) and often carried aminoglycoside-associated resistance genes. The majority of the <i>erm</i>-positive isolates were obtained from chicken. The increasing rates of <i>erm</i>-positive and multiresistant isolates make the monitoring of erythromycin-resistant <i>Campylobacter</i> strains, specifically within the chicken meat production, a topic of serious importance.

Authors

Institutions

Publication Details

Journal
Antimicrobial Agents and Chemotherapy
Published
2024-12-31
DOI
https://doi.org/10.1128/aac.01668-24
Citations
4
Primary Topic
Salmonella and Campylobacter epidemiology
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Increasing rates of erm (B) and erm (N) in human Campylobacter coli and Campylobacter jejuni erythromycin-resistant isolates between 2018 and 2023 in France

Laurent Gillet, Lucie Bénéjat, Quentin Jehanne, Philippe Lehours et al.
4 citations
Antimicrobial Agents and Chemotherapy
Salmonella and Campylobacter epidemiology
1.39
article

Increasing rates of erm (B) and erm (N) in human Campylobacter coli and Campylobacter jejuni erythromycin-resistant isolates between 2018 and 2023 in France

Laurent Gillet, Lucie Bénéjat, Quentin Jehanne, Philippe Lehours, Marine Jauvain, Johanna Aptel, Astrid Ducournau, Marie Pivard
article en
4 citations

Abstract

Macrolides are the first-line compounds used for the treatment of campylobacteriosis. Macrolide resistance remains low in France, with mutations in <i>23S rDNA</i> being the main associated resistance mechanism. However, two erythromycin methyltransferases have also been identified<i>: erm</i>(B), which is mainly described in animal reservoirs, and <i>erm</i>(N), which is strictly described in humans. In France, between 2018 and 2023, erythromycin-resistant <i>Campylobacter</i> species strains were systematically sequenced and analyzed <i>via</i> an in-house bioinformatics pipeline, leading to the identification of the resistomes, MLST and cgMLST, as well as the characterization of the source of contamination. In this study, the genomes of 280 erythromycin-resistant strains were sequenced over a 6-year period. The identification of erythromycin-associated resistance markers revealed a predominance of <i>23S rDNA</i> mutations, in 90% of cases, but also <i>erm</i>-type methyltransferases in 10% of cases: 75% for <i>erm</i>(N) and 25% for <i>erm</i>(B). Over this period, an important increase in the rate of <i>erm</i>-positive isolates was observed: 2% in 2018 compared with 13% in 2023, with 10% for <i>erm</i>(N) and 3% for <i>erm</i>(B). <i>erm</i>(N) has been found exclusively within a CRISPR-Cas9 operon, whereas <i>erm</i>(B) has been found within diverse types of resistance genomic islands. Each <i>erm</i>(N)- or <i>erm</i>(B)-positive isolate had at least two other resistance markers (mostly ciprofloxacin, tetracycline, or ampicillin) and often carried aminoglycoside-associated resistance genes. The majority of the <i>erm</i>-positive isolates were obtained from chicken. The increasing rates of <i>erm</i>-positive and multiresistant isolates make the monitoring of erythromycin-resistant <i>Campylobacter</i> strains, specifically within the chicken meat production, a topic of serious importance.

Antimicrobial Agents and ChemotherapyVol. 69(2)
Université de Bordeaux (FR), Inserm (FR), Bordeaux Population Health (FR), Laboratoire National de Référence (MA), BoRdeaux Institute of onCology (FR)
Life below water
Openalex Percentile: Top 18%
Salmonella and Campylobacter epidemiology
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.